Anapa Biotech
Develops molecular tools to enhance the performance of natural nucleic acids.
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Anapa Biotech A/S, based in Copenhagen, specializes in molecular research tools with a unique intellectual property portfolio and a pioneering approach to high-throughput nucleic acid assays. The company’s core innovation is its multiplex PCR method, which allows the combination of 25 PCR assays in a single tube, significantly enhancing diagnostic speed and reducing costs. Anapa Biotech serves a diverse range of clients, including those in human and veterinary diagnostics, food and feed quality and safety, environmental surveillance, and scientific research. Operating in the biotechnology market, Anapa Biotech generates revenue through the sale of its proprietary diagnostic tools and technologies. The company’s business model focuses on leveraging its novel multiplexing method to provide superior diagnostic solutions that improve efficiency and accuracy in various applications.
Keywords: multiplex PCR, nucleic acid assays, diagnostics, biotechnology, molecular research, intellectual property, high-throughput, cost-effective, Copenhagen, innovative technology.